RecruitingNCT06771193

Study on Disease Characteristics and Treatment in Locally Advanced or Recurrent / Metastatic Cervical Cancer in Italy

RETRACE Study - Retrospective Observational Study Evaluating Disease Characteristics and Treatment Landscape of High-risk Locally Advanced (LA) or Recurrent / Metastatic (R/M) Cervical Cancer in Italy

Sponsor

MSD Italia S.r.l.

Enrollment

200 participants

Start Date

Dec 17, 2024

Study Type

OBSERVATIONAL

Conditions

Cervical Cancer Locally Advanced Cervical Cancer Recurrent Cervical Cancer Metastatic Cervical Cancer

Summary

Multicenter, Observational, Retrospective charts review. Observational study with descriptive purpose only. Retrospective data capture in consecutive patients diagnosed with CC who attended the Oncologic Clinics from Jan 2018 to Dec 2021 (using medical records, either electronic or not), inserted in eCRF and analyzed.

Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria5

Patient (or their legally acceptable representatives) must have signed and dated the Informed Consent \& Privacy Form (ICF)
Age ≥18 years
Diagnosis of a cervical cancer
Locally advanced stage (not suitable for curative surgery) or recurrent or metastatic disease
Any treatment received between January 2018 and December 2021 for advanced disease

Exclusion Criteria3

Patients participating in a pharmacological clinical trial for the treatment of advanced disease
Patients who participated in a clinical trial
Patients who were administered with Pembrolizumab, Olaparib or Levantinib or medications from these class of drugs

Locations(11)

Oncologia Medica Policlinico Sant'Orsola Malpighi

Bologna, Bologna, Italy

Ginecologia ed Ostetricia A.O. Cannizzaro

Catania, Catania, Italy

Oncologia Medica 1 IRCCS Ospedale Policlinico San Martino

Genova, Genova, Italy

Unità di Ginecologia Oncologica Medica IRCCS Ospedale San Raffaele

Milan, Milano, Italy

Unità Ostetricia, Ginecologia e Ginecologia Oncologica medica Humanitas San Pio X

Milan, Milano, Italy

Oncologia A.O.U. di Modena - Policlinico

Modena, Modena, Italy

U.O.S. Trattamenti Innovativi dell'utero Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale

Napoli, Napoli, Italy

UOC Oncologia Medica ed Ematologia Azienda Ospedaliera Universitaria Luigi Vanvitelli

Napoli, Napoli, Italy

IRCCS Centro di Riferimento Oncologico (CRO)

Aviano, Pordenone, Italy

U.O.C. Ginecologia Oncologica Policlinico Agostino Gemelli

Roma, Roma, Italy

UOC Oncologia Medica Ospedale Dell'Angelo - Mestre Azienda USL3 Serenissima

Mestre, Venezia, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06771193

Related Trials

ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

NCT0697316127 locations

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

NCT049774538 locations

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

NCT0721670360 locations

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

NCT06459180239 locations

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

NCT074721531 location